<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1-368-00
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2000
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        OPTIMOL 0.25% OPHTHALMIC SOLUTION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TIMOLOL MALEATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        %
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Ophthalmic use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Eye drops, solution
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Dropper Container
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        25.80
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jamjoom Pharmaceuticals Factory Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 394]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            JAMJOOM PHARMACEUTICALS CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory  Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        S01ED01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active ingredient timolol belongs to a group of<br />medicines called beta-blockers.<br />OptimolTM is used to treat raised pressure of eye<br />(intraocular pressure) which occurs in various<br />conditions including glaucoma and ocular<br />hypertension.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; are allergic (hypersensitive) to timolol maleate or<br />beta-blockers or to any other ingredient of this<br />medicine (see section 6. for more details).<br />&bull; if you have now or have had in past respiratory<br />problems such as asthma, severe chronic obstructive<br />bronchitis (severe lung disease which may cause<br />wheeziness, difficulty in breathing and/or<br />long-standing cough).<br />&bull;if you have a slow heart beat, heart failure or<br />disorders of heart rhythm (irregular heart beats).<br />Take special care with Optimol&trade;<br />Before you use Optimol&trade; please tell your doctor<br />if you have now or have had in the past:<br />&bull; coronary heart disease (symptoms can include<br />chest pain or tightness, breathlessness or choking),<br />heart failure, low blood pressure.<br />&bull; breathing problems, asthma or chronic obstructive<br />pulmonary disease.<br />&bull; poor blood circulation disease (such as Raynaud&rsquo;s<br />disease or Raynaud&rsquo;s syndrome).<br />&bull; diabetes as Optimol&trade; may mask signs and<br />symptoms of low blood sugar.<br />&bull; overactivity of the thyroid gland as Optimol&trade; may<br />mask signs and symptoms.<br />Tell your doctor before you have an operation that<br />you are using Optimol&trade; as it may change effects of<br />some medicines used during anaesthesia.<br />Paediatric population:<br />Optimol&trade; eye drop solution should generally be<br />used with caution in young patients. In newborns,<br />infants and younger children Optimol&trade; should be<br />used with extreme caution. If coughing, wheezing,<br />abnormal breathing or abnormal pauses in breathing<br />(apnoea) occur, the use of the medication should be<br />stopped immediately. Contact your doctor as soon as<br />possible. A portable apnoea monitor may also be<br />helpful.<br />Timolol has been studied in infants and children<br />aged 12 days to 5 years, who have raised pressure in<br />the eye(s) or have been diagnosed with glaucoma.<br />For more information, talk to your doctor.<br />Using other medicines<br />Optimol&trade; can affect or be affected by other<br />medicines you are using, including other eye drops<br />for the treatment of glaucoma. Tell your doctor if<br />you are using or intend to use medicines to lower<br />blood pressure, heart medicine or medicines to treat<br />diabetes. Please tell your doctor or pharmacist if you<br />are taking or have recently taken any other<br />medicines, including medicines obtained without a<br />prescription. In particular:<br />&bull; a calcium antagonist (e.g. verapamil or diltiazem)<br />often used to treat high blood pressure, angina, or an<br />abnormal heartbeat.<br />&bull; digoxin, often used to treat heart failure or an<br />abnormal heartbeat.<br />&bull; medicines known as a catecholamine-depleting<br />agents (e.g. rauwolfia alkaloids/reserpine) used to<br />treat high blood pressure.<br />&bull; a pressor amine (e.g. adrenaline) used to treat<br />severe allergic reaction.<br />&bull; clonidine to treat high blood pressure.<br />&bull; quinidine, a medicine used to treat heart conditions<br />and some types of malaria.<br />&bull; other beta-blockers (e.g. other preparations of<br />timolol both oral and/or ocular), which belong to the<br />same group of medicines.<br />&bull; antidepressants known as fluoxetine and<br />paroxetine.<br />Pregnancy and breast-feeding<br />Do not use Optimol&trade; if you are pregnant unless your<br />doctor considers it necessary.<br />Do not use Optimol&trade; if you are breast-feeding.<br />Timolol may get into your milk.<br />Ask your doctor for advice before taking any<br />medicine during breast-feeding.<br />Driving and using machines<br />No effects on ability to drive and use machines have<br />been reported. However do not drive or operate<br />machines if you experience any visual disturbance<br />after using the product. Wait until this clears before<br />driving or using machines.<br />Important information about some of the<br />ingredients of Optimol&trade; Eye Drops:<br />The eye drops contain benzalkonium chloride as<br />preservative which may cause eye irritation. Avoid<br />contact with soft contact lenses. Remove contact<br />lenses before using the eye drops and wait at least 15<br />minutes before reinserting. The preservative is<br />known to discolour soft contact lenses.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use Optimol&trade; exactly as your doctor has<br />told you. You should check with your doctor or<br />pharmacist if you are not sure.<br />The usual starting dose is one drop of 0.25% eye<br />drops into each affected eye(s) twice daily,<br />approximately 12 hours apart. Your doctor will<br />change your treatment dose as necessary.<br />If you are using in combination with another eye<br />drop medicine, wait 5-15 minutes before applying<br />the second eye drop.<br />Posology:<br />Paediatric population:<br />A detailed medical examination should precede the<br />use of Optimol&trade;. Your doctor will carefully evaluate<br />the risks and benefits when considering treatment<br />with Optimol&trade;. If the benefits outweigh the risks, it<br />is recommended to use the lowest active agent<br />concentration available once daily. With regard to<br />&ldquo;the use in children&rdquo;, the 0.1% active agent<br />concentration may be sufficient to control pressure<br />within the eye. If the pressure is not sufficiently<br />controlled with this dosage, a twice daily application<br />at 12&ndash;hourly intervals may be necessary. Patients,<br />especially newborn, should be closely observed for<br />one to two hours after the first dose and careful<br />monitoring for adverse events should be carried out<br />until surgery is performed.<br />Instructions for use:<br />&bull; Unscrew the cap from the bottle, check the dropper<br />is clean.<br />&bull; Pull your lower eyelid gently down, and then<br />carefully instill one drop inside the lower eyelid, in<br />the corner closest to the nose.<br />&bull; Release the lower eyelid, and blink a few times to<br />make sure the eye is covered by the liquid.<br />&bull; After using Optimol&trade;, press a finger into the<br />corner of your eye, by the nose for 3-5 minutes. This<br />helps to stop Optimol&trade; getting into the rest of the<br />body.<br />&bull; Repeat the procedure for your other eye, if it also<br />needs treatment.<br />&bull; When you have finished, replace the protective cap<br />tightly to prevent spilling or spoilage.<br />Duration of treatment:<br />For a transient treatment in the paediatric population.<br />Be careful not to touch the tip of the bottle on your<br />eye or on any other surface.<br />Ocular solutions if handled wrongly can become<br />contaminated by common bacteria and cause eye<br />infections.</p><p>If you do develop any other eye condition whilst<br />using this product, see your doctor immediately.<br />Keep using your medicine until your doctor tells you<br />to stop.<br />If you use more OptimolTM than you should<br />If you accidentally use too much, contact your<br />doctor or go to the nearest hospital casualty<br />department immediately.<br />Overdose : There is no experience of an overdosage<br />with Optimol&trade; which is unlikely when given as eye<br />drops. The signs of overdosage include slow heart<br />rate, drop of blood pressure, breathing difficulties,<br />and heart attack.<br />If you forget to use Optimol&trade;<br />Apply the drops as soon as you remember. However,<br />if it is almost time for your next dose, do not double<br />your dose and carry on with the normal schedule<br />dose.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Optimol&trade; can cause side effects,<br />although not everybody gets them. You can usually<br />carry on taking the drops, unless the effects are<br />serious. If you&#39;re worried, talk to a doctor or<br />pharmacist.<br />Do not stop using Optimol&trade; without speaking to<br />your doctor.<br />If you experience a rare (these may affect between 1<br />in 1,000 and 1 in 10,000 patients) but serious<br />allergic reaction (difficulty breathing, closing of the<br />throat, swelling of the lips, tongue, or face or hives)<br />to Optimol&trade;, stop using the medication and contact<br />your doctor immediately.<br />Like other medicines applied into eyes, OptimolTM is<br />absorbed into the blood. This may cause similar side<br />effects as seen with intraveneous&#39; and/or &#39;oral&#39; as<br />applicable beta-blocking agents. Incidence of side<br />effects after topical ophthalmic administration is<br />lower than when medicines are, for example, taken<br />by mouth or injected. Listed side effects include<br />reactions seen within the class of beta-blockers<br />when used for treating eye conditions:<br />&bull; Generalized allergic reactions including swelling<br />beneath the skin that can occur in areas such as the<br />face and limbs, and can obstruct the airway which<br />may cause difficulty swallowing or breathing, hives<br />or itchy rash, localized and generalized rash,<br />itchiness, severe sudden life-threatening allergic<br />reaction.<br />&bull; Low blood glucose levels.<br />&bull; Difficulty sleeping (insomnia), depression,<br />nightmares, memory loss.<br />&bull; Signs and symptoms of eye irritation (e.g. burning,<br />stinging, itching, tearing, redness), inflammation of<br />the eyelid, inflammation in the cornea, blurred<br />vision and detachment of the layer below the retina<br />that contains blood vessels following filtration<br />surgery which may cause visual disturbances,<br />decreased corneal sensitivity, dry eyes, corneal<br />erosion (damage to the front layer of the eyeball),<br />drooping of the upper eyelid (making the eye stay<br />half closed), conjunctivitis, double vision.<br />&bull; Slow heart rate, chest pain, palpitations, oedema<br />(fluid build up), changes in the rhythm or speed of<br />the heartbeat, congestive heart failure (heart disease<br />with shortness of breath and swelling of the feet and<br />legs due to fluid build up), a type of heart rhythm<br />disorder, heart block, heart failure, heart attack, low<br />blood pressure, Raynaud&#39;s phenomenon, cold hands<br />and feet.<br />&bull; Constriction of the airways in the lungs<br />(predominantly in patients with pre-existing<br />disease), difficulty breathing, nasal congestion,<br />cough.<br />&bull; Taste disturbances, loss of appetite, nausea,<br />indigestion, diarrhoea, dry mouth, abdominal pain,<br />vomiting.<br />&bull; fainting, stroke, reduced blood supply to the brain,<br />increased signs and symptoms of myasthenia gravis<br />(weakness, drooping eyelids, double vision, muscle<br />disorder), dizziness, unusual sensations (like pins<br />and needles), and headache.<br />&bull; Hair loss, skin rash with white silvery coloured<br />appearance (psoriasiform rash) or worsening of<br />psoriasis, skin rash.<br />&bull; Muscle pain not caused by exercise.<br />&bull; Sexual dysfunction, decreased libido.<br />&bull; Muscle weakness, tiredness.<br />&bull; Depression, anxiety or psychiatric disturbances.<br />If any of the side effects get serious, or if you notice<br />any side effects not mentioned in this leaflet, please<br />tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep out of the reach and sight of children.<br />&bull; Do not store above 30 &deg;C. Protect from light.<br />&bull; Once opened the drops should not be used for<br />longer than 1 month.<br />&bull; Do not use Optimol&trade; after the expiry date which is<br />stated on the bottle and on the carton.<br />&bull; Medicines should not be disposed of via waste<br />water or household waste. Ask your pharmacist how<br />to dispose of medicines no longer required. These<br />measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active ingredient is timolol maleate, where<br />5mg/ml timolol is equivalent to 6.8mg/ml of timolol<br />maleate and 2.5mg/ml timolol is equivalent to<br />3.4mg/ml of timolol maleate.<br />The other ingredients are benzalkonium chloride,<br />sodium hydroxide, sodium phosphate dibasic<br />anhydrous, sodium phosphate monobasic<br />monohydrate and water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Optimol™ Ophthalmic Solution is a clear, colorless
to yellow color solution, free from visible
contamination.
Optimol™ 0.25% Sterile Ophthalmic solution, 5mI in
LDPE opaque bottles.
Optimol™ 0.5% Sterile Ophthalmic solution, 5mI in
LDPE opaque bottles.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><br />Jamjoom Pharmaceuticals Co.,<br />Jeddah, Saudi Arabia.<br />Tel: +966-12-6081111, Fax: +966-12-6081222<br />Website: www.jamjoompharma.com<br />To report any side effect(s):<br />&bull; Saudi Arabia:<br />The National Pharmacovigilance and Drug Safety<br />Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222,<br />Ext: 2317-2356-2340.<br />o Reporting hotline: 19999<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />&minus; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                10-2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>&bull; تنتمي المادة الفعالة تیمولول إلى مجموعة من الأدویة تسمى<br />&quot;حاصرات بیتا&quot;.<br />لعلاج الضغط المرتفع داخل العینین &trade; &bull; تُستخدم أوبتیمول<br />(ضغط العین) والذي یحدث في حالات مختلفة تشمل<br />الجلوكوما و فرط ضغط العین.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; إذا كنت تعاني من فرط الحساسیة لمالیات التیمولول أو<br />الأخرى &trade; لحاصرات بیتا أو أي من مكونات الأوبتیمول<br />(أنظر الجزء السادس لمزید من التفاصیل).<br />&bull; إذا كنت تعاني حالیاً أو فیما سبق من مشاكل في الجھاز<br />التنفسي مثل نوبات الربو والتھاب القصبات الھوائیة المزمن<br />الحاد ( وھو نوع من الأمراض الرئویة الحادة التي قد تسبب<br />الأزیز، صعوبة في التنفس و/ أو السعال لفترة طویلة).<br />&bull; إذا كان لدیك بطء في ضربات القلب، قصور في القلب أو<br />اضطرابات في إیقاع ضربات القلب (خفقان القلب).<br />&trade; إتخذ إحتیاطات خاصة عند استخدام أوبتیمول<br />برجاء أبلاغ طبیبك إذا كنت تعاني &trade; قبل استخدام أوبتیمول<br />حالیا أو فیما سبق من:<br />&bull; أمراض القلب التاجیة (وتشمل الأعراض ألم أو ضیق في<br />الصدر، ضیق في التنفس أو اختناق)، قصور في القلب،<br />إنخفاض في ضغط الدم، مشاكل في التنفس، نوبات ربو أو<br />مرض الإنسداد الرئوي المزمن.<br />&bull; ضعف في الدورة الدمویة (مثل مرض رینود أو متلازمة<br />رینود).<br />علامات &trade; &bull; مرض السكر حیث یمكن أن تخفي أوبتیمول<br />وأعراض انخفاض السكر في الدم.<br />العلامات &trade; &bull; فرط نشاط الغدة الدرقیة یمكن أن تخفي أوبتیمول<br />والأعراض.<br />&bull; أخبر طبیبك قبل الخضوع للعملیات الجراحیة حیث أن<br />قد یغیر تأثیر بعض الأدویة المستخدمة &trade; استخدام أوبتیمول<br />أثناء التخدیر.<br />الأطفال:<br />للعین عموما بحذر في &trade; &bull; یجب استخدام قطرة أوبتیمول<br />المرضى صغار السن. و یكون استخدامھا بحذر شدید في<br />الأطفال حدیثي الولادة و الرضع والأطفال صغار السن.<br />&bull; إذا حدث سعال وصفیر عند التنفس، وتنفس غیر طبیعي أو<br />أوضاع غیر طبیعیة في التنفس (توقف التنفس)، فإن استخدام<br />الدواء یجب أن یتوقف فورا. إتصل بطبیبك في أسرع وقت<br />ممكن. یمكن أن یكون جھار مراقبة التنفس المحمول مفیدا في<br />ھذه الحالات.<br />&bull; لقد تم دراسة استخدام تیمولول للأطفال في سن ما بین ۱۲<br />یوماً إلى ٥ سنوات والذین یعانون من إرتفاع في ضغط العین<br />في إحدى العینین أو كلتاھما أو تم تشخیص حالتھم بالجلوكوما.<br />لمزید من المعلومات تحدث إلى طبیبك.<br />إستخدام أدویة أخرى:<br />على أو تتأثر باستخدام الأدویة &trade; یمكن أن تؤثر أوبتیمول<br />الأخرى التي تستخدمھا، بما في ذلك قطرات العین الأخرى<br />التي تستعمل لعلاج الجلوكوما. أخبر طبیبك إذا كنت تستخدم<br />أو تنوي استخدام أدویة لخفض ضغط الدم، أو أدویة القلب أو<br />أدویة علاج مرض السكري.<br />من فضلك قم بإخبار الطبیب أو الصیدلي الخاص بك إذا كنت<br />تتناول أو تناولت مؤخرا أي أدویة أخرى بما في ذلك الأدویة<br />التي یتم صرفھا بدون وصفة طبیة. علي الخصوص:<br />&bull; مضادات الكالسیوم (مثل الفیرابامیل أو الدیلتیازیم) والتي<br />تستخدم عادة لعلاج ضغط الدم المرتفع، الذبحة الصدریة أو<br />اضطراب نبضات القلب.<br />&bull; أدویة تُعرف باسم عوامل استنفاذ الكاتیكولامین (مثل<br />قلویدات الراوفولفیا/ ریسیربین) وتستخدم لعلاج ضغط الدم<br />المرتفع.<br />&bull; الأمینات الرافعة للضغط (مثل الأدرینالین) ویستخدم لعلاج<br />الحساسیة الشدیدة.<br />&bull; الكلونیدین لعلاج ضغط الدم المرتفع.<br />&bull; الكینیدین، وھو دواء یستخدم لعلاج أمراض القلب وبعض<br />أنواع من الملاریا.<br />&bull; أنواع أخرى من حاصرات بیتا (مثل الأشكال الأخرى من<br />التیمولول التي تؤخذ عن طریق الفم و/أو العین)، والتي تنتمي<br />لنفس المجموعة من الأدویة.<br />&bull; مضادات الإكتئاب التي تُعرف بالفلوكسیتین والباروكسیتین.<br />الحمل و الرضاعة الطبیعیة:<br />إذا كنتِ حاملاً ما لم یرى الطبیب &trade; &bull; لا تستخدمي أوبتیمول<br />ضرورة لذلك.<br />إذا كنتِ ترضعین طبیعیاً. فقد تمر &trade; &bull; لا تستخدمي أوبتیمول<br />من خلال لبن الأم. &trade; أوبتیمول<br />&bull; إستشیري طبیبك قبل تناول أي دواء أثناء الرضاعة<br />الطبیعیة.<br />القیادة و استخدام الآلات:<br />لم یتم الإبلاغ عن حدوث أعراض جانبیة تؤثر على القیادة أو<br />تشغیل الآلات ومع ذلك لا تقم بالقیادة أو تشغیل الآلات إذا<br />واجھت أي اضطراب في الرؤیة بعد استخدام ھذا المنتج.<br />انتظر حتى تزول تلك الأعراض قبل القیادة أو استخدام<br />الآلات.<br />للعین: &trade; معلومات ھامة عن بعض مكونات قطرة أوبتیمول<br />للعین على كلورید البنزالكونیوم &trade; &bull; تحتوي قطرة أوبتیمول<br />كمادة حافظة والذي یمكن أن یسبب تھیج بالعین. تجنب تلامس<br />مع العدسات اللاصقة. انزع العدسات اللاصقة قبل &trade; أوبتیمول<br />للعین ثم انتظر &trade; استخدام قطرة أوبتیمول<br />۱٥ دقیقة قبل وضع العدسات اللاصقة في عینیك مرة أخرى.<br />تلك المادة الحافظة معروفة بأنھا تتسبب في تغییر لون<br />العدسات اللاصقة اللینة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>للعین تماماً كما وصفھا لك &trade; &bull; استخدم دائما قطرة أوبتیمول<br />الطبیب. إذا كنت غیر متأكداً فینبغي علیك التحقق من طبیبك<br />أو الصیدلي.<br />&bull; جرعة البدایة المعتادة ھي نقطة واحدة من قطرة العین<br />۰٫۲٥ ٪ في إحدى العینین المصابتین أو كلتیھما مرتین في<br />الیوم تقریباً كل ۱۲ ساعة.<br />&bull; سوف یقوم طبیبك بتغییر جرعة العلاج حسب الضرورة.<br />مع قطرات أخرى للعین، انتظر &trade; &bull; إذا كنت تستخدم أوبتیمول<br />۱٥ دقیقة قبل استخدام قطرة العین الأخرى. -٥<br />الجرعات:<br />الأطفال:<br />إجراء فحص طبي &trade; ینبغي أن یسبق استخدام أوبتیمول<br />مفصل. سوف یقوم طبیبك بتقییم المخاطر والفوائد عند الأخذ<br />بعنایة. إذا كانت الفوائد تفوق &trade; في الاعتبار العلاج بأوبتیمول<br />المخاطر، فمن المستحسن استخدام أقل تركیز متاح من المادة<br />الفعالة مرة واحدة یومیا. فیما یتعلق ب&quot; الاستخدام في الأطفال<br />&quot;، قد یكون تركیز ۰,۱ ٪ من المادة الفعالة كافٍ للسیطرة على<br />الضغط المرتفع داخل العین. إذا لم یتم التحكم في ضغط العین<br />عن طریق ھذه الجرعة بشكل كافٍ، فمن الممكن أن یكون<br />تناول جرعة مرتین في الیوم كل ۱۲ ساعة ضروریاً. ینبغي<br />مراعاة المرضى وبشكل خاص الأطفال حدیثي الولادة عن<br />كثب لمدة ساعة إلى ساعتین بعد الجرعة الأولى والرصد<br />بشكل دقیق للآثار الجانبیة حتى یتم إجراء الجراحة.<br />تعلیمات الاستخدام:<br />&bull; قم بلف الغطاء من الزجاجة، وتحقق من أن القطارة نظیفة.<br />&bull; إسحب الجفن السفلي إلى أسفل برفق، ومن ثم ضع بعنایة<br />قطرة واحدة داخل الجفن السفلي، في الزاویة الأقرب إلى<br />الأنف.<br />&bull; حرر الجفن السفلي، أغلق وافتح العین عدة مرات للتأكد من<br />تغطیة العین عن طریق السائل.<br />اضغط بإصبعك على الركن حیث &trade; &bull; بعد استخدام أوبتیمول<br />٥ دقائق. - تلتقي الأنف بالعین و استمر على ذلك لمدة من ۳<br />إلى باقي &trade; سوف یساعد ذلك على منع وصول أوبتیمول<br />أجزاء الجسم.<br />في كلتا العینین كرر نفس &trade; &bull; إذا كنت تستخدم أوبتیمول<br />الخطوات للعین الأخرى.إذا كانت ھي أیضاً تحتاج للعلاج.<br />&bull; قم بإعادة غطاء الزجاجة الى مكانھ مباشرة بعد الإستخدام<br />وقم بإحكام الغلق.<br />مدة العلاج:<br />للعلاج لفترة مؤقتة في الأطفال.<br />كن حریصاً على ألَّا یتم ملامسة طرف الزجاجة لعینك أو لأي<br />سطح آخر.</p><p>إذا ما تم استخدام قطرات العین بشكل خاطئ یمكن أن تصبح<br />ملوثة بالبكتیریا الشائعة ویتسبب ذلك عادةً في حدوث عدوى<br />بكتیریة بالعین .اذا واجھت أي حالات أخرة بالعین أثناء<br />استخدام ھذا المنتج، قم بزیارة طبیبك على الفور.<br />إستمر في استخدام الدواء الخاص بك حتى یخبرك الطبیب<br />بالتوقف.<br />للعین بكمیة أكثر من &trade; إذا استخدمت قطرة أوبتیمول<br />المطلوب:<br />أكثر من اللازم عن طریق الخطأ، &trade; إذا استخدمت أوبتیمول<br />اتصل بطبیبك أو اذھب إلى قسم الطوارىء بأقرب مستشفى<br />على الفور.<br />الجرعة المفرطة: من غیر المرجح حدوث مشاكل لفرط<br />كقطرة للعین. &trade; الجرعة عند استخدام أوبتیمول<br />علامات الجرعة المفرطة تشمل بطء معدل ضربات القلب،<br />وانخفاض ضغط الدم وصعوبة في التنفس ونوبات القلب.<br />:&trade; إذا نسیت استخدام أوبتیمول<br />ضع قطرة العین حینما تتذكر. ومع ذلك، إذا كان وقت<br />الجرعة التالیة قد حان تقریبا، فلا تقم بمضاعفة الجرعة<br />واستمر في تناول الجرعات وفقاً للجدول الزمني المعتاد.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل كل الأدویة الأخرى, یمكن أن تتسبب أوبتیمول<br />حدوث أعراضاً جانبیة بالرغم من عدم تعرض جمیع<br />الأشخاص لھا.<br />- یمكنك دائماً أن تستمر في استخدام القطرة إلَّا إذا كانت<br />الأعراض الجانبیة خطیرة. إذا كنت قلقاً تحدث إلى طبیبك أو<br />الصیدلي.<br />بدون التحدث إلى طبیبك. &trade; لا تتوقف عن استخدام أوبتیمول<br />&trade; إذا واجھت تفاعلات تحسسیة نادرة عن استخدام أوبتیمول<br />۱,۰۰۰ مریض) ولكنھا خطیرة / (یمكن أن تؤثر على ۱<br />(صعوبة في التنفس، وانسداد في الحلق، تورم في الشفتین<br />واللسان، أو الوجھ أو بثور)، توقف عن استخدام ھذا الدواء،<br />واتصل بطبیبك على الفور.<br />في الدم مثلھا في ذلك مثل باقي الأدویة &trade; تُمتص أوبتیمول<br />التي تُستخدم عن طریق العین. یمكن أن یتسبب ذلك في<br />حدوث آثاراً جانبیة مثل تلك التي تُلاحظ عند استخدام<br />حاصرات بیتا عن طریق الفم أو الحقن الوریدي.<br />معدل حدوث الآثار الجانبیة بعد استخدام قطرات العین<br />الموضعیة أقل من تلك التي تحدث على سبیل المثال، إذا تم<br />تناول الأدویة عن طریق الفم أو الحقن.</p><p>الآثار الجانبیة المدرجة:<br />- تشمل تفاعلات تظھر عند استخدام فئة الأدویة من حاصرات<br />بیتا لعلاج أمراض العین. حساسیة بشكل عام بما في ذلك<br />تورم تحت الجلد والذي یمكن أن یحدث في مناطق مثل الوجھ<br />والأطراف، ویمكن ان یسد القنوات الھوائیة مما قد یسبب<br />صعوبة في البلع أو التنفس، بثور أو طفح مصحوب بحكة،<br />وطفح جلدي موضعي أو عام، حكة، ردود فعل تحسسیة<br />مھددة للحیاة تحدث بشكل مفاجئ.<br />- انخفاض مستویات السكر في الدم.<br />- صعوبة في النوم (الأرق)، واكتئاب، كوابیس، وفقدان في<br />الذاكرة.<br />- علامات وأعراض تھیج العین (على سبیل المثال حرق،<br />وخز، والحكة، تدمیع، واحمرار)، التھاب الجفن، التھاب في<br />القرنیة، عدم وضوح الرؤیة وانفصال الطبقة الموجودة تحت<br />الشبكیة والمحتویة على أوعیة دمویة بعد جراحة الترشیح<br />والذي یمكن أن یتسبب في حدوث اضطرابات في الرؤیة<br />ونقص في حساسیة القرنیة، جفاف بالعین، تقرح بالقرنیة،<br />تلف بالطبقة الأمامیة من مقلة العین. ارتخاء في الجفن العلوى<br />من العین (حیث تظھر العین و كأنھا نصف مفتوحة) ،التھاب<br />الملتحمة و ازدواج بالرؤیة.<br />- بطء معدل ضربات القلب، ألم في الصدر، وخفقان، تورم<br />(تجمع السوائل)، تغییرات في إیقاع أو سرعة ضربات القلب،<br />وقصور القلب الاحتقاني (أمراض قلبیة مصحوبة بضیق في<br />التنفس وتورم في القدمین والساقین بسبب تجمع السوائل)،<br />وھو نوع من اضطراب إیقاع ضربات القلب، إنسداد شریاني،<br />قصور القلب، والنوبات القلبیة، وانخفاض ضغط الدم،<br />متلازمة رینود، وبرودة في الیدین والقدمین.<br />- انقباض في الشعب الھوائیة للرئتین (في الغالب یحدث ذلك<br />مع المرضى الذین یعانون من وجود مرض مسبقا)، صعوبة<br />في التنفس، واحتقان في الانف وسعال.<br />- اضطرابات في حاسة التذوق، فقدان الشھیة، غثیان، عسر<br />في الھضم، إسھال، جفاف بالفم، آلام في البطن، قيء.<br />- إغماء، سكتة دماغیة، انخفاض تدفق الدم إلى الدماغ، وزیادة<br />علامات وأعراض الوھن العضلي الوبیل (ضعف، ارتخاء<br />الجفون، إزدواج الرؤیة، واضطرابات في العضلات)، دوخة،<br />الشعور بأشیاء غیر طبیعیة (مثل الوخز والتنمیل، صداع).<br />- تساقط الشعر، طفح جلدي مع مظھر أبیض مائل إلى اللون<br />الفضي (طفح جلدي صدفي) أو تفاقم مرض الصدفیة، طفح<br />جلدي.<br />- آلام في العضلات غیر ناجمة عن ممارسة الریاضة.<br />- ضعف الجنسي، انخفاض الرغبة الجنسیة.<br />- ضعف في العضلات، والشعور بالإرھاق.<br />- اكتئاب أو قلق أو اضطرابات نفسیة.<br />إذا لاحظت تحول أي من الآثار الجانبیة إلى مرحلة أكثر<br />خطورة أو إذا ظھرت أیة آثار جانبیة أخرى غیر مدرجة في<br />ھذه النشرة فیرجى إخبار طبیبك أو الصیدلي بھا.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>- یُحفظ بعیداً عن متناول و مرأى الأطفال.<br />م. یُحفظ بعیداً عن &ordm; - یُحفظ في درجة حرارة لا تزید عن ۳۰<br />الضوء.<br />- لا یستعمل الدواء بعد ۳۰ یوما من تاریخ فتح الزجاجة.<br />للعین بعد انتھاء تاریخ &trade; - لا تستخدم قطرة أوبتیمول<br />الصلاحیة و المدون على الزجاجة وعلى العبوة الكرتونیة.<br />- لا یتم التخلص من الأدویة عن طریق میاه الصرف أو<br />النفایات المنزلیة. إسأل الصیدلي عن طریقة التخلص من<br />الأدویة الغیر مرغوب فیھا فسوف تساعد ھذه الإجراءات<br />على حمایة البیئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ما ھي مكونات أوبتیمول<br />المادة الفعالة ھي مالیات التیمولول حیث أن<br />٦ ملجم/مل مالیات التیمولول &cedil; ٥ ملجم/مل تیمولول تكافيء ۸<br />۳ ملجم/مل مالیات &cedil; ۲ملجم/مل تیمولول تكافيء ٤ &cedil; و ٥<br />التیمولول.<br />المكونات الأخرى ھي كلورید البنزالكونیوم، ھیدروكسید<br />الصودیوم، فوسفات الصودیوم ثنائى القاعدة اللامائي،<br />فوسفات الصودیوم أحادي القاعدة أحادي الماء و ماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right">محلول للعین رائق عدیم اللون إلى أصفر اللون &trade; أوبتیمول<br />خالي من الجزیئات العالقة.<br />٥ مل في قطارة من البولي إیثیلین ، ٪۰,۲٥ &trade; أوبتیمول<br />منخفض الكثافة .<br />٥ مل في قطارة من البولي إیثیلین ، ٪۰,٥ &trade; أوبتیمول<br />منخفض الكثافة .</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>اسم وعنوان مالك رخصة التسویق و المصنع:<br />شركة مصنع جمجوم للأدویة،<br />جدة، المملكة العربیة السعودیة.<br />+۹٦٦-۱۲- ھاتف: ٦۰۸۱۱۱۱<br />+۹٦٦-۱۲- فاكس: ٦۰۸۱۲۲۲<br />www.jamjoompharma.com : الموقع الإلكتروني<br />للإبلاغ عن أي أثار جانبیھ:<br />&bull; المملكة العربیة السعودیة:<br />- المركز الوطني للتیقظ و السلامة الدوائیة<br />+۹٦٦-۱۱-۲۰٥- فاكس: ۷٦٦۲ o<br />للإتصال بالإدارة التنفیذیة للتیقظ وإدارة الأزمات. o<br />+۹٦٦-۱۱- ھاتف: ۲۰۳۸۲۲۲ o<br />۲۳٤۰-۲۳٥٦- تحویلة: ۲۳۱۷<br />الخط الساخن للإبلاغ: ۱۹۹۹۹ o<br />npc.drug@sfda.gov.sa : برید إلكتروني o<br />www.sfda.gov.sa/npc : الموقع الالكتروني o<br />&bull; دول الخلیج الأخرى:<br />- الرجاء الاتصال بالمؤسسات و الھیئات الوطنیة في كل<br />دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            10-2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Optimol™ 0.5% Sterile Ophthalmic Solution 5ml
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each ml contains: Timolol Maleate 6.84 mg ( equivalent to timolol 5.0 mg)
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Eye drops solution.
Clear, colourless to straw color solution, free from visible contamination, filled in 10ml
LDPE opaque bottles.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&#39;Optimol 0.5%&#39; Eye Drops Solution is a beta-adrenoreceptor blocking agent used topically in<br />the reduction of elevated intra-ocular pressure in various conditions including the following:<br />patients with ocular hypertension; patients with chronic open-angle glaucoma including<br />aphakic patients; some patients with secondary glaucoma.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>If clinical response is not adequate, dosage may be changed to one drop 0.5% solution in<br />each affected eye twice a day. If needed, &#39;Optimol&#39; may be used with other agent(s) for<br />lowering intra-ocular pressure. The use of two topical beta-adrenergic blocking agents is not<br />recommended (see 4.4 &#39;Special warnings and precautions for use&#39;).<br />Intra-ocular pressure should be reassessed approximately four weeks after starting treatment<br />because response to &#39;Optimol&#39; may take a few weeks to stabilise.<br />Provided that the intra-ocular pressure is maintained at satisfactory levels, many patients can<br />than be placed on once-a-day therapy.<br />Transfer from other agents&nbsp;</p><p>When another topical beta-blocking agent is being used, discontinue its use after a full day<br />of therapy and start treatment with &#39;Optimol&#39; the next day with one drop of 0.25% &#39;Optimol&#39;<br />in each affected eye twice a day. The dosage may be increased to one drop of 0.5% solution<br />in each affected eye twice a day, if the response is not adequate.<br />When transferring a patient from a single anti-glaucoma agent other than a topical betablocking<br />agent, continue the agent and add one drop of 0.25% &#39;Optimol&#39; in each affected eye<br />twice a day. On the following day, discontinue the previous agent completely, and continue<br />with &#39;Optimol&#39;. If a higher dosage of &#39;Optimol&#39; is required, substitute one drop of 0.5%<br />solution in each affected eye twice a day.<br />&#39;Optimol&#39; Eye Drops Solution is also available as &#39;Optimol&#39; Unit dose: The Unit-dose<br />Dispenser of &#39;Optimol&#39; is free from preservative and should be used for patients who may be<br />sensitive to the preservative benzalkonium chloride, or when use of a preservative-free<br />topical medication is advisable.<br />Paediatric use: is not currently recommended.<br />Use in the elderly: there has been wide experience with the use of timolol maleate in elderly<br />patients. The dosage recommendations given above reflect the clinical data derived from this<br />experience.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Bronchial asthma, history of bronchial asthma or severe chronic obstructive pulmonary
disease; sinus bradycardia, second- and third-degree AV block, overt cardiac failure,
cardiogenic shock; and hypersensitivity to this product or other beta-blocking agents.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Like other topically applied ophthalmic drugs, &#39;Optimol&#39; may be absorbed systemically and<br />adverse reactions seen with oral beta-blockers may occur.<br />Cardiac failure should be adequately controlled before beginning therapy with &#39;Optimol&#39;.<br />Patients with a history of severe cardiac disease should be watched for signs of cardiac<br />failure and have their pulse rates checked.<br />Respiratory and cardiac reactions, including death due to bronchospasm in patients with&nbsp;asthma and, rarely, death associated with cardiac failure have been reported.<br />The effect on intra-ocular pressure or the known effects of systemic beta-blockade may be<br />exaggerated when &#39;Optimol&#39; is given to the patients already receiving a systemic betablocking<br />agent. The response of these patients should be closely observed. The use of two<br />topical beta-adrenergic blocking agents is not recommended.<br />There have been reports of skin rashes and/or dry eyes associated with the use of betaadrenoreceptor<br />blocking drugs. The reported incidence is small and in most cases the<br />symptoms have cleared when treatment was withdrawn. Discontinuation of the drug should<br />be considered if any such reaction is not otherwise explicable. Cessation of therapy<br />involving beta-blockade should be gradual.<br />Choroidal detachment has been reported with administration of aqueous suppressant therapy<br />(e.g. timolol, acetazolamide) after filtration procedures.<br />&#39;Optimol&#39; has been generally well tolerated in glaucoma patients wearing conventional hard<br />contact lenses. &#39;Optimol&#39; has not been studied in patients wearing lenses made with material<br />other than polymethylmethacrylate (PMMA), which is used to make hard contact lenses.<br />The Ocumeter&reg; Dispenser of &#39;Optimol&#39; contains benzalkonium chloride as a preservative<br />which may be deposited in soft contact lenses; therefore &#39;Optimol&#39; should not be used while<br />wearing these lenses. The lenses should be removed before application of the drops and not<br />reinserted earlier than 15 minutes after use.&nbsp;</p><p>In patients with angle-closure glaucoma, the immediate objective of treatment is to reopen<br />the angle. This requires constricting the pupil with a miotic. &#39;Optimol&#39; has little or no effect<br />on the pupil. When &#39;Optimol&#39; is used to reduce elevated intra-ocular pressure in angleclosure<br />glaucoma it should be used with a miotic and not alone.<br />Patients should be advised that if they develop an intercurrent ocular condition (e.g. trauma,<br />ocular surgery or infection), they should immediately seek their physician&#39;s advice<br />concerning the continued use of the present multidose container (see 6.6 &#39;Special precautions<br />for disposal and other handling&#39;).<br />There have been reports of bacterial keratitis associated with the use of multiple dose<br />containers of topical ophthalmic products. These containers had been inadvertently<br />contaminated by patients who, in most cases, had a concurrent corneal disease or a<br />disruption of the ocular epithelial surface.<br />Risk from anaphylactic reaction: While taking beta-blockers, patients with a history of atopy&nbsp;or a history of severe anaphylactic reaction to a variety of allergens may be more reactive to<br />repeated challenge with such allergens, either accidental, diagnostic, or therapeutic. Such<br />patients may be unresponsive to the usual doses of epinephrine (adrenaline) used to treat<br />anaphylactic reactions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Although &#39;Optimol&#39; alone has little or no effect on pupil size, mydriasis has occasionally<br />been reported when &#39;Optimol&#39; is given with epinephrine (adrenaline).<br />Potentiated systemic beta-blockade (e.g. decreased heart rate, depression) has been reported<br />during combined treatment with CYP2D6 inhibitors (e.g.quinidine, SSRIs) and timolol.<br />Oral &beta;-adrenergic blocking agents may exacerbate the rebound hypertension which can<br />follow the withdrawal of clonidine.<br />&#39;Optimol&#39; may potentially add to the effects of oral calcium antagonists, rauwolfia alkaloids<br />or beta-blockers, to induce hypotension and/or marked bradycardia.<br />Close observation of the patient is recommended when a beta-blocker is administered to<br />patients receiving catecholamine-depleting drugs such as reserpine, because of possible<br />additive effects and the production of hypotension and/or marked bradycardia, which may<br />produce vertigo, syncope, or postural hypotension.<br />Oral calcium antagonists may be used in combination with beta-adrenergic blocking agents<br />when heart function is normal, but should be avoided in patients with impaired cardiac<br />function.<br />The potential exists for hypotension, AV conduction disturbances and left ventricular failure<br />to occur in patients receiving a beta-blocking agent when an oral calcium entry blocker is<br />added to the treatment regimen. The nature of any cardiovascular adverse effect tends to<br />depend on the type of calcium blocker used. Dihydropyridine derivatives, such as nifedipine,<br />may lead to hypotension, whereas verapamil or diltiazem have a greater propensity to lead to<br />AV conduction disturbances or left ventricular failure when used with a beta-blocker.</p><p>Intravenous calcium channel blockers should be used with caution in patients receiving betaadrenergic<br />blocking agents.<br />The concomitant use of beta-adrenergic blocking agents and digitalis with either diltiazem<br />or verapamil may have additive effects in prolonging AV conduction time.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Use in pregnancy: &#39;Optimol&#39; has not been studied in human pregnancy. The use of &#39;Optimol&#39;<br />requires that the anticipated benefit be weighed against possible hazards.<br />Breast-feeding mothers: Timolol is detectable in human milk. A decision for breast-feeding<br />mothers, either to stop taking &#39;Optimol&#39; or stop nursing, should be based on the importance<br />of the drug to the mother.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Possible side effects such as dizziness and visual disturbances may affect some patients&#39;<br />ability to drive or operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Side effects<br />&#39;Optimol&#39; is usually well tolerated. The following adverse reactions have been reported with<br />ocular administration of this or other timolol maleate formulations, either in clinical trials or<br />since the drug has been marketed. Additional side effects have been reported in clinical<br />experiences with systemic timolol maleate, and may be considered potential effects of<br />ophthalmic timolol maleate:<br />Special senses:<br />ocular: signs and symptoms of ocular irritation, including burning and stinging,<br />conjunctivitis, blepharitis, keratitis, dry eyes and decreased corneal sensitivity. Tinnitus,<br />visual disturbances, including refractive changes (due to withdrawal of miotic therapy in<br />some cases), diplopia, ptosis and choroidal detachment following filtration surgery (see 4.4<br />&#39;Special warnings and precautions for use&#39;).<br />Cardiovascular:<br />ocular: bradycardia, arrhythmia, hypotension, syncope, heart block, cerebrovascular<br />accident, cerebral ischaemia, congestive heart failure, palpitation, cardiac arrest, oedema,<br />claudication, Raynaud&#39;s phenomenon, cold hands and feet.</p><p>systemic: AV block (second- or third-degree), sino-atrial block, pulmonary oedema,<br />worsening of arterial insufficiency, worsening of angina pectoris, vasodilation.<br />Respiratory:<br />ocular: bronchospasm (predominantly in patients with pre-existing bronchospastic disease),<br />respiratory failure, dyspnoea, cough.<br />systemic: rales<br />Body as a whole:<br />ocular: headache, asthenia, fatigue, chest pain.<br />systemic: extremity pain, decreased exercise tolerance.<br />Integumentary:<br />ocular: alopecia, psoriasiform rash or exacerbation of psoriasis.<br />systemic: pruritus, sweating, exfoliative dermatitis.<br />Hypersensitivity:<br />ocular: signs and symptoms of allergic reactions including anaphylaxis, angioedema,<br />urticaria, localised and generalised rash.<br />Nervous system/psychiatric:<br />ocular: dizziness, depression, insomnia, nightmares, memory loss, increase in signs and<br />symptoms of myasthenia gravis, paresthesia.<br />systemic: vertigo, local weakness, diminished concentration, increased dreaming.<br />Digestive:<br />ocular: nausea, diarrhoea, dyspepsia, dry mouth.<br />systemic: vomiting&nbsp;</p><p>Urogenital:<br />ocular: decreased libido, Peyronie&#39;s disease.<br />systemic: impotence, micturition difficulties.<br />Immunologic:<br />ocular: systemic lupus erythematosus<br />Endocrine:<br />systemic: hyperglycaemia, hypoglycaemia.<br />Musculoskeletal:<br />systemic: arthralgia.<br />Haematologic:<br />systemic: non-thrombocytopenic purpura.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There have been reports of inadvertent overdosage with &#39;Optimol&#39; resulting in systemic<br />effects similar to those seen with systemic beta-adrenergic blocking agents such as<br />dizziness, headache, shortness of breath, bradycardia, bronchospasm, and cardiac arrest (see<br />&#39;Side effects&#39;).<br />If overdosage occurs, the following measures should be considered:<br />1. Gastric lavage, if ingested. Studies have shown that timolol does not dialyse readily.<br />2. Symptomatic bradycardia: atropine sulphate, 0.25 to 2 mg intravenously, should be used<br />to induce vagal blockade. If bradycardia persists, intravenous isoprenaline hydrochloride<br />should be administered cautiously. In refractory cases, the use of a cardiac pacemaker may<br />be considered.<br />3. Hypotension: a sympathomimetic pressor agent such as dopamine, dobutamine or&nbsp;noradrenaline should be used. In refractory cases, the use of glucagon has been reported to<br />be useful.<br />4. Bronchospasm: isoprenaline hydrochloride should be used. Additional therapy with<br />aminophylline may be considered.<br />5. Acute cardiac failure: conventional therapy with digitalis, diuretics, and oxygen should be<br />instituted immediately. In refractory cases, the use of intravenous aminophylline is<br />suggested. This may be followed, if necessary, by glucagon, which has been reported useful.<br />6. Heart block (second- or third-degree): isoprenaline hydrochloride or a pacemaker should<br />be used.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Timolol maleate is a non-selective beta-adrenergic receptor blocking agent that does not<br />have significant intrinsic sympathomimetic, direct myocardial depressant, or local<br />anaesthetic activity. Timolol maleate combines reversibly with the beta-adrenergic receptor,<br />and this inhibits the usual biologic response that would occur with stimulation of that<br />receptor. This specific competitive antagonism blocks stimulation of the beta-adrenergic<br />stimulating (agonist) activity, whether these originate from an endogenous or exogenous<br />source. Reversal of this blockade can be accomplished by increasing the concentration of the<br />agonist which will restore the usual biological response.<br />Unlike miotics, &#39;Optimol&#39; reduces IOP with little or no effect on accommodation or pupil<br />size. In patients with cataracts, the inability to see around lenticular opacities when the pupil<br />is constricted is avoided. When changing patients from miotics to &#39;Optimol&#39; a refraction<br />might be necessary when the effects of the miotic have passed.<br />Diminished response after prolonged therapy with &#39;Optimol&#39; has been reported in some<br />patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The onset of reduction in intra-ocular pressure can be detected within one-half hour after a<br />single dose. The maximum effect occurs in one or two hours; significant lowering of IOP&nbsp;can be maintained for as long as 24 hours with a single dose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No adverse ocular effects were observed in rabbits and dogs administered &#39;Optimol&#39; topically<br />in studies lasting one and two years, respectively. The oral LD50 of the drug is 1,190 and 900<br />mg/kg in female mice and female rats, respectively.<br />Carcinogenesis, mutagenesis, impairment of fertility<br />In a two-year oral study of timolol maleate in rats there was a statistically significant<br />(p&le;0.05) increase in the incidence of adrenal phaeochromocytomas in male rats<br />administered 300 mg/kg/day (300 times the maximum recommended human oral dose).<br />Similar differences were not observed in rats administered oral doses equivalent to 25 or 100<br />times the maximum recommended human oral dose.<br />In a lifetime oral study in mice, there were statistically significant (p&le;0.05) increases in the<br />incidence of benign and malignant pulmonary tumours, benign uterine polyps and mammary<br />adenocarcinoma in female mice at 500 mg/kg/day (500 times the maximum recommended<br />human dose), but not at 5 or 50 mg/kg/day. In a subsequent study in female mice, in which<br />post-mortem examinations were limited to uterus and lungs, a statistically significant<br />increase in the incidence of pulmonary tumours was again observed at 500 mg/kg/day.<br />The increased occurrence of mammary adenocarcinoma was associated with elevations in<br />serum prolactin which occurred in female mice administered timolol at 500 mg/kg/day, but<br />not at doses of 5 or 50 mg/kg/day. An increased incidence of mammary adenocarcinomas in<br />rodents has been associated with administration of several other therapeutic agents which<br />elevate serum prolactin, but no correlation between serum prolactin levels and mammary<br />tumours has been established in man. Furthermore, in adult human female subjects who<br />received oral dosages of up to 60 mg of timolol maleate, the maximum recommended<br />human oral dosage, there were no clinically meaningful changes in serum prolactin.<br />Timolol maleate was devoid of mutagenic potential when evaluated in vivo (mouse) in the<br />micronucleus test and cytogenetic assay (doses up to 800 mg/kg) and in vitro in a neoplastic<br />cell transformation assay (up to 100 mcg/ml). In Ames tests the highest concentrations of<br />timolol employed, 5,000 or 10,000 mcg/plate, were associated with statistically significant<br />(p&le;0.05) elevations of revertants observed with tester strain TA100 (in seven replicate<br />assays) but not in the remaining three strains. In the assays with tester strain TA100, no<br />consistent dose-response relationship was observed, nor did the ratio of test to control<br />revertants reach 2. A ratio of 2 is usually considered the criterion for a positive Ames test.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium phosphate monobasic monohydrate<br />Sodium phosphate dibasic anhydrous<br />Sodium hydroxide<br />Benzalkonium chloride<br />Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 Years
Discard after 30 days of opening.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Immediate container: LDPE (Low-Density Polyethylene) bottle 24-25 mm dia; white<br />(around 1% TiO2), round shape with rounded shoulder; indented ring<br />for tamper evident cap locking mechanism.<br />Cap: HDPE (High-Density Polyethylene) white (around 1% TiO2), round<br />shape with locking ring.<br />Nozzle: LDPE (Low-Density Polyethylene) Nozzle White (around 1.6%<br />TiO2).<br />Outer carton: 280g/m2 grammage paper, dimension 29 mm x 29.5 mm x 73 mm,<br />printing as per drawing.</p><p>Label: 20 x 73 mm, self adhesive<br />Insert/leaflet: 50-60 g/m2 paper, dimension 140 x 120 mm, both sides printed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients should be instructed to avoid allowing the tip of the dispensing container to contact<br />the eye or surrounding structures.<br />Patients should also be instructed that ocular solutions, if handled improperly, can become<br />contaminated by common bacteria known to cause ocular infections. Serious damage to the<br />eye and subsequent loss of vision may result from using contaminated solutions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jamjoom Pharmaceuticals Company Limited
Plot No. ME1:3, Phase V, Industrial city,
P.O. Box 6267, Jeddah 21442,
Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                22-05-2007
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>